SMA Newsroom

Sep 20, 2023

Community update from Scholar Rock

We are happy to share with you the latest update shared with us by Scholar Rock.

The company announced yesterday that it has completed enrollment of the SAPPHIRE Phase 3 trial evaluating the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) who are receiving SMN therapy (either nusinersen or risdiplam).

You can read full press release below.